Blood group systems
Over 250 different antigens have been found on the surface of red blood cells (RBCs) but the most important of these belong to the ABO system. A and B antigens are important because patients who lack one or both of the antigens form antibodies against the absent antigen(s). These circulating antibodies can fix complement and produce intravascular haemolysis. They are naturally occurring without earlier antigenic stimulation. In this way, group A patients produce anti-B antibodies, group B patients produce anti-A antibodies and group O patients produce both anti-A and anti-B antibodies.
Whilst the majority of AB patients produce no circulating antibodies and can receive any blood group, the situation is complicated by the existence of group A1 and A2 subgroups. A1 equals approximately 80% of the entire A blood type population and A2 makes up the remaining 20%. Group A2/A2B patients form A1 antibodies.
Five major antigens in the Rh system are D, C, c, E and e and, of these, the RhD antigen is highly immunogenic and thus clinically significant. 15% of the population is rhesus negative (Rh-ve) and they are at risk of an immune-mediated transfusion reaction.
There are a large number of other blood groups identified but the Kell antibodies and Kidd antibodies are amongst those known to be associated with transfusion reactions.
Before receiving their blood transfusion, patients are typed for ABO and Rh and the patient's serum is screened for antibodies to other non-ABO blood groups. If agglutination occurs, serum is tested further to identify antibodies present.
Increasingly, new technology is being used to cross-match blood which utilises DNA genotyping. This enables a much wider range of antigens to be tested for, enabling the identification of rarer blood groups. This is particularly significant for compatibility testing.
Before being transfused to a patient, donor red cells are mixed with the patient's serum and, if no reaction occurs, the unit is considered compatible. In an extreme life-threatening situation there may not be enough time to perform this, in which case it is permissable to use group O Rh-ve red cells until testing is possible.
Blood and blood products
In most circumstances, blood component therapy has replaced the use of whole blood. However, whole blood is still occasionally used for massive transfusion in circumstances in which rapid correction of acidosis, hypothermia and coagulopathy is required. This mainly occurs in military situations for trauma patients who require resuscitation.
Red blood cells (RBCs)
RBCs are prepared from whole blood by removal of most of the plasma. They are indicated in both acute haemorrhage and chronic anaemia. Red cell units have a haematocrit of 70% (citrate phosphate dextrose adenine (COPD-1) solution) or 55-60% (additive solutions (AS)) with a shelf life of 35 days and 42 days respectively when refrigerated at 1-6°C. A decision to give a transfusion should be reached both on the patient's clinical situation and on laboratory findings, not on Hb alone.
Transfusion is often not considered until Hb <7 g/dL but patients with unstable angina or acute myocardial infarction may require transfusion at Hb <10 g/dL. A single unit of red blood will typically increase Hb by 1g/dL. Other RBC products include leukocyte-reduced components, which can reduce febrile reactions and are an alternative to cytomegalovirus (CMV)-seronegative components and prevent HLA alloimmunisation. Also, washed components (RBC and platelets) remove harmful plasma antibodies.
Each unit of platelets is prepared from a single whole blood collection by differential centrifugation and contains at least 5.5 x 1010 platelets in 50 ml of plasma. They are stored at 20-24°C in plastic containers under agitation and have a shelf life of five days. Each unit can raise platelet count by 5-10 x 109/L. Alternatively, platelets are prepared by apheresis (a process of filtration), contain >3 x 1011 platelets suspended in 200 ml plasma, and are equivalent to six random donor platelet units. Platelets are not usually cross-matched with the recipient, but ABO type-specific platelets should be provided where possible as, otherwise, the increment is 10-20% less in platelet count. Platelets are given to patients with thrombocytopenia who are bleeding or those with severe thrombocytopenia, as a precaution. Patients rarely bleed spontaneously when platelet count is >20 x 109/L and patients receiving chemotherapy can often tolerate counts of 5-10 x 109/L.
These are mainly given to neutropenic cancer patients developing bacterial sepsis unresponsive to conventional antibiotic therapy for at least 24-48 hours. Preparations collected from normal donors by apheresis contain at least 1 x 1010 neutrophils/unit; however, the concentration can be increased by using donors stimulated by steroids and/or growth factors. Granulocyte preparations can only be stored for 24 hours at 20-24°C. They need to be cross-matched with the recipient's serum because of the large number of red cells they contain and need to be irradiated because of the large number of lymphocytes present.
Granulocytes are only usually considered for patients with an absolute neutrophil count <0.5 x 109/L and a good chance of marrow recovery. They usually need to be given daily until patients can maintain an absolute neutrophil count >0.5 x 109/L without transfusion or until the infection has resolved. Patients frequently have a febrile reaction to granulocytes and these are more severe when amphotericin is infused at around the time of the granulocyte infusion.
Fresh frozen plasma (FFP)
FFP is produced by centrifugation of one donation of whole blood and collection of the supernatant liquid.The plasma is frozen within eight hours of collection, in order to maintain the activity of factor V and factor VII. The main indication for FFP is deficiency of multiple coagulation factors found in liver disease and disseminated intravascular coagulation (DIC) and forms part of massive transfusion protocols in major trauma or in major obstetric, gastrointestinal tract or surgical haemorrhage. It is also often used for urgent reversal of warfarin anticoagulation. Because of the large volume that would be required, FFP is not generally used to replace individual clotting factors. In these situations specific factors are given (see under 'Factor' headings, below).
Cryoprecipitate is made by thawing FFP at 1-6°C and is generally used for patients with von Willebrand's disease or severe hypofibrinaemia. A commercial preparation of solvent/detergent-treated frozen human plasma called Octaplas® is available but needs ABO compatibility checks. Uniplas® is a human plasma product which has been shown to be independent of ABO compatibility but it is not yet widely used in the UK.
In the UK this is available as isotonic (4.5% and 5%) or concentrated (20%) solutions for the treatment of hypovolaemia and hypoalbuminaemia.The cost-benefit of albumin in the treatment of hypovolaemia is controversial but it is still used in the management of liver disease and ascites.It is tested for hepatitis C virus (HCV) RNA and virally inactivated, and not considered as a risk factor for viral transmission. Its use has now largely been superseded by non-plasma colloidal solutions.
Intravenous (IV) immunoglobulin is used in the treatment of immuno-thrombocytopenia, Guillain-Barré syndrome and autoimmune haemolytic anaemias. RhD immunoglobulin is used to prevent exposure to D-positive red cells causing Rh sensitisation in D-negative patients. This is usually given in pregnancy and immediately after birth to prevent haemolytic disease of the newborn in future babies.
Antithrombin III concentrate
This is prepared from human plasma and used to treat congenital deficiency of antithrombin III; side-effects include flushing, nausea, headache and (rarely) fever and allergic reactions.
Factor VIIa (recombinant)
This is used in patients with inhibitors to factors VIII and IX and is indicated in patients with haemophilia A and B. Theoretical concerns about an increased risk of deep vein thrombosis and pulmonary embolus have not been borne out in randomised trials.
Factor VIII fraction, dried
Also known as human antihaemophilic fraction, this is prepared from human plasma by a suitable fractionation technique and indicated for the treatment and prophylaxis of haemorrhage in haemophilia A. Large or frequently repeated doses in patients with blood groups A, B or AB can lead to intravascular haemolysis. This is less likely to occur with high-potency purified concentrates. Side-effects include allergic reactions, chills and fever.
Factor VIII inhibitor bypassing fractions
This is prepared from human plasma and is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in haemophilia A and haemophilia B patients with inhibitors.It has also been used in non-haemophiliac patients with acquired inhibitors to factors VIII, XI and XII.Intravascular coagulation is the main adverse effect.
Dried factor IX fraction
This is prepared from fractionating human plasma and may also contain factors II, VII, and X. It is used for the treatment of haemophilia B (congenital factor IX deficiency) or acquired haemophilia.The risk of thrombosis has largely been obviated by increasing the purity of the product. Side-effects include allergic reactions, chills and fever; however, these are usually infrequent and mild.
Factor XIII dried
This is also known as human fibrin-stabilising factor and is indicated for congenital factor XIII deficiency. Adverse effects, which include allergic reactions and fever, are rare. Recombinant factor XIII has been shown to be a safe and effective alternative in trials.
Protein C concentrate
This is prepared from human plasma. It is indicated in congenital protein C deficiency, a congenital disorder characterised by an increased tendency to coagulation.
Complications of transfusion
See also the separate Blood Transfusion Reactions article.
- Infection - eg, hepatitis B, hepatitis C, HIV, Creutzfeldt-Jakob disease.
- Acute non-infectious:
- Acute haemolytic reaction.
- Allergic reaction.
- Anaphylactic reaction.
- Coagulation problems in massive transfusion.
- Febrile non-haemolytic reaction.
- Metabolic derangements.
- Mistransfusion (transfusion of the incorrect product to the incorrect recipient).
- Septic or bacterial contamination.
- Transfusion-associated circulatory overload.
- Transfusion-related acute lung injury.
- Urticarial reaction.
- Delayed non-infectious:
- Delayed haemolytic reaction.
- Iron overload.
- Over-transfusion or under-transfusion.
- Post-transfusion purpura.
- Transfusion-associated graft-versus-host disease.
- Transfusion-related immunomodulation.
Did you find this information useful?
- Blood transfusion; NICE Guidelines (November 2015)
- Blood transfusion; NICE Quality Standard, December 2016
- Dean L; Blood Groups and Red Cell Antigens, 2005
- Repine TB, Perkins JG, Kauvar DS, et al; The use of fresh whole blood in massive transfusion. J Trauma. 2006 Jun 60(6 Suppl):S59-69.
- British National Formulary; NICE Evidence Services (UK access only)
- Solheim BG, Granov DA, Juravlev VA, et al; Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang. 2005 Jul 89(1):19-26.
- Barrio J, Carrera MD, Sanmiguel G, et al; Acute lung injury related to transfusion of fresh frozen plasma. Rev Esp Anestesiol Reanim. 2004 Jun-Jul 51(6):342-5.
- Mendez CM, McClain CJ, Marsano LS; Albumin therapy in clinical practice. Nutr Clin Pract. 2005 Jun 20(3):314-20.
- Shao YF, Yang JM, Chau GY, et al; Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb 191(2):245-9.
- Feiba® VH Immuno; Drugs.com
- Maddox JM, Anderson JA, Plews D, et al; Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia. 2005 Nov 11(6):633-7.
- Johansen RF, Sorensen B, Ingerslev J; Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia. 2006 Mar 12(2):190-7.
- Lovejoy AE, Reynolds TC, Visich JE, et al; Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 1 108(1):57-62. Epub 2006 Mar 23.
- Sharma S, Sharma P, Tyler LN; Transfusion of blood and blood products: indications and complications. Am Fam Physician. 2011 Mar 15 83(6):719-24.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.